X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will aid in the clinical development of first-in-class antibiotics, with the potential to meet an unmet medical need in the hospital-based treatment of severe infections like those caused by E. coli and K. pneumoniae.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Funding April 09, 2024
Details:
Zevtera (ceftobiprole medocaril sodium) is approved for adult patients with S. aureus bloodstream infections, and adult patients with acute bacterial skin and skin structure infections and for adult and pediatric patients with community-acquired bacterial pneumonia.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
Under the licensing agreement, Knight will focus on the Cresemba (isavuconazole sulfate) to commercialize in Latin America. It is an approved azole antifungal product indicated for the treatment of adult patients with invasive aspergillosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Knight Therapeutics
Deal Size: Undisclosed Upfront Cash: $11.2 million
Deal Type: Licensing Agreement January 19, 2024
Details:
Through the acquisition, Basilea gains a preclinical program of antibiotics from a novel class, targeting Gram-negative bacteria, including multidrug-resistant strains.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Spexis
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 15, 2024
Details:
Pfizer has the right to manufacture Cresemba, an intravenous, oral azole antifungal, and exclusively commercialize the drug in Europe, the Asia Pacific and China regions. Isavuconazonium sulfate has been approved in 73 countries for invasive aspergillosis and mucormycosis.
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $1,095.4 million Upfront Cash: $72.3 million
Deal Type: Licensing Agreement November 20, 2023
Details:
Basilea has acquired the rights to PF-07842805 (fosmanogepix), a potential first-in-class, clinical-stage broad-spectrum antifungal treatment candidate for the treatment of Candidemia, including Candida auris, and invasive mold infections.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Product Name: PF-07842805
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Pfizer Inc
Deal Size: $147.0 million Upfront Cash: $37.0 million
Deal Type: Acquisition November 13, 2023
Details:
Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license LSVT-1701 (tonabacase) for further clinical development and commercialization.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: LSVT-1701
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: iNtRON Biotechnology
Deal Size: $CHECK CHECK Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 31, 2023
Details:
Under the agreement, Basilea will investigate SAL200 (tonabacase), a potential first-in-class clinical-stage antibacterial of the endolysin class, against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: SAL200
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: iNtRON Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 31, 2023
Details:
Under the agreement, iNtRON grants Basilea exclusive right for preclinical evaluation of the antibacterial bio-drug N-Rephasin SAL200 (tonabacase), a novel endolysin-based anti-staphylococcal drug formulated for injection.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: N-Rephasin SAL200
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: iNtRON Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2023
Details:
Through the acquisition, Basilea gains GR-2397, a clinical-stage antifungal compound with a novel mechanism of action, targeting invasive mold infections caused by Aspergillus species.
Lead Product(s): BAL2062
Therapeutic Area: Infections and Infectious Diseases Product Name: BAL2062
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Gravitas Therapeutics
Deal Size: $70.7 million Upfront Cash: $2.0 million
Deal Type: Acquisition October 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
